Genomtec (GMT) Q2 2024 earnings summary

Executive summary

• Genomtec S.A. focuses on R&D in biotechnology, with its main project, Genomtec ID, in the industrialization phase and ongoing efforts to commercialize diagnostic solutions.

• The company is listed on the Warsaw Stock Exchange and relies on equity and grants for funding, with recent share issues and grant inflows supporting operations.

Financial highlights

• Net loss for H1 2024 was PLN 6,040 thousand, compared to a net loss of PLN 4,056 thousand in H1 2023.

• Revenue from sales remained minimal at PLN 1 thousand, with grant revenue at PLN 801 thousand for H1 2024.

• Cash and cash equivalents increased to PLN 14,062 thousand as of June 30, 2024, from PLN 4,169 thousand at year-end 2023.

• Share capital increased to PLN 1,332 thousand (13,324,570 shares) following a new share issue in H1 2024.

• Total assets rose to PLN 24,865 thousand as of June 30, 2024, up from PLN 15,972 thousand at December 31, 2023.

Outlook and guidance

• Management expects continued negative results and cash flows until commercialization of developed technologies.

• Additional share issues may be required to finance commercialization; break-even is targeted post-commercialization.